Log in

NASDAQ:DFFNDiffusion Pharmaceuticals Stock Price, Forecast & News

$1.08
-0.01 (-0.92 %)
(As of 08/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.07
Now: $1.08
$1.13
50-Day Range
$0.83
MA: $1.08
$1.50
52-Week Range
$0.21
Now: $1.08
$2.42
Volume1.54 million shs
Average Volume5.05 million shs
Market Capitalization$52.06 million
P/E RatioN/A
Dividend YieldN/A
Beta1.4
Diffusion Pharmaceuticals Inc., a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer and metastatic brain cancer; and Phase II trial for the treatment of acute stroke. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. was founded in 2001 and is headquartered in Charlottesville, Virginia.
Read More
Diffusion Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DFFN
CUSIPN/A
Phone434-220-0718

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.60 per share

Profitability

Net Income$-11,800,000.00

Miscellaneous

Employees10
Market Cap$52.06 million
Next Earnings Date11/9/2020 (Estimated)
OptionableNot Optionable
$1.08
-0.01 (-0.92 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DFFN News and Ratings via Email

Sign-up to receive the latest news and ratings for DFFN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Diffusion Pharmaceuticals (NASDAQ:DFFN) Frequently Asked Questions

How has Diffusion Pharmaceuticals' stock been impacted by COVID-19?

Diffusion Pharmaceuticals' stock was trading at $0.3434 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, DFFN stock has increased by 214.5% and is now trading at $1.08.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Diffusion Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diffusion Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Diffusion Pharmaceuticals
.

When is Diffusion Pharmaceuticals' next earnings date?

Diffusion Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 9th 2020.
View our earnings forecast for Diffusion Pharmaceuticals
.

How were Diffusion Pharmaceuticals' earnings last quarter?

Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) issued its earnings results on Monday, August, 10th. The company reported ($0.06) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.06).
View Diffusion Pharmaceuticals' earnings history
.

When did Diffusion Pharmaceuticals' stock split? How did Diffusion Pharmaceuticals' stock split work?

Diffusion Pharmaceuticals shares reverse split on Friday, December 14th 2018. The 1-15 reverse split was announced on Thursday, December 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 13th 2018. An investor that had 100 shares of Diffusion Pharmaceuticals stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for DFFN?

1 equities research analysts have issued 1 year price targets for Diffusion Pharmaceuticals' shares. Their forecasts range from $3.50 to $3.50. On average, they anticipate Diffusion Pharmaceuticals' share price to reach $3.50 in the next year. This suggests a possible upside of 224.1% from the stock's current price.
View analysts' price targets for Diffusion Pharmaceuticals
.

Has Diffusion Pharmaceuticals been receiving favorable news coverage?

Press coverage about DFFN stock has trended negative recently, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Diffusion Pharmaceuticals earned a news impact score of -2.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about Diffusion Pharmaceuticals
.

Are investors shorting Diffusion Pharmaceuticals?

Diffusion Pharmaceuticals saw a drop in short interest during the month of June. As of June 30th, there was short interest totaling 461,700 shares, a drop of 49.1% from the June 15th total of 906,400 shares. Based on an average trading volume of 6,400,000 shares, the short-interest ratio is presently 0.1 days.
View Diffusion Pharmaceuticals' Short Interest
.

Who are some of Diffusion Pharmaceuticals' key competitors?

What other stocks do shareholders of Diffusion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Diffusion Pharmaceuticals investors own include Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Matinas BioPharma (MTNB), BioNano Genomics (BNGO), ADMA Biologics (ADMA), Novan (NOVN), Zosano Pharma (ZSAN), AEterna Zentaris (AEZS), Gran Tierra Energy (GTE) and OrganiGram (OGI).

Who are Diffusion Pharmaceuticals' key executives?

Diffusion Pharmaceuticals' management team includes the following people:
  • Mr. David G. Kalergis, Co-Founder, CEO & Chairman (Age 70)
  • Dr. John L. Gainer, Co-Founder, Chief Scientific Officer & Director (Age 80)
  • Mr. William Karl Hornung, Chief Financial Officer (Age 50)
  • Mr. Thomas E. Byrne, Gen. Counsel (Age 62)
  • Dr. David Randolph Jones M.D., Sr. Medical Advisor (Age 56)

What is Diffusion Pharmaceuticals' stock symbol?

Diffusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "DFFN."

Who are Diffusion Pharmaceuticals' major shareholders?

Diffusion Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.12%), HCR Wealth Advisors (0.08%) and UBS Group AG (0.06%).

Which institutional investors are selling Diffusion Pharmaceuticals stock?

DFFN stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG.

Which institutional investors are buying Diffusion Pharmaceuticals stock?

DFFN stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC, and HCR Wealth Advisors.

How do I buy shares of Diffusion Pharmaceuticals?

Shares of DFFN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Diffusion Pharmaceuticals' stock price today?

One share of DFFN stock can currently be purchased for approximately $1.08.

How big of a company is Diffusion Pharmaceuticals?

Diffusion Pharmaceuticals has a market capitalization of $52.06 million. The company earns $-11,800,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Diffusion Pharmaceuticals employs 10 workers across the globe.

What is Diffusion Pharmaceuticals' official website?

The official website for Diffusion Pharmaceuticals is www.diffusionpharma.com.

How can I contact Diffusion Pharmaceuticals?

Diffusion Pharmaceuticals' mailing address is 1317 CARLTON AVENUE SUITE 200, CHARLOTTESVILLE VA, 22902. The company can be reached via phone at 434-220-0718 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.